等待开盘 05-19 09:30:00 美东时间
+0.040
+0.45%
今日重点评级关注:HC Wainwright & Co.:维持Artiva Biotherapeutics"买入"评级,目标价从15美元升至35美元;韦德布什:维持Cullinan Therapeutics"跑赢大市"评级,目标价从36美元升至37美元
05-11 15:43
今日重点评级关注:Citizens:维持BioCryst制药"跑赢大市"评级,目标价从25美元升至28美元;富国银行:维持曼恩凯德生物医疗"超配"评级,目标价从8美元升至10美元
05-08 12:05
UBS analyst Joshua Chan maintains TIC Solutions (NYSE:TIC) with a Neutral and raises the price target from $8 to $11.
05-08 07:10
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
TIC Solutions shares are trading higher after the company reported better-than-...
05-07 00:03
Acuren (NYSE:TIC) held its first-quarter earnings conference call on Wednesday....
05-06 21:21
TIC Solutions (NYSE:TIC) affirms FY2026 sales outlook from $2.150 billion-$2.250 billion to $2.150 billion-$2.250 billion vs $2.183 billion estimate.
05-06 19:07
Acuren (NYSE:TIC) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.12) by 58.33 percent. This is a 9.52 percent increase over losses of $(0.21) per share from the same
05-06 19:02
TIC Solutions Q1 FY26 net loss widens to $41.55 million; revenue more than doubled to $488.03 million TIC Solutions posted a net loss of $41.55 million as revenue more than doubled to $488.03 million. Operating loss widened to $29.06 million from $9.44 million, while interest expense, net climbed 81
05-06 18:59
TIC Solutions Q1 net loss widens to $41.5 million; revenue more than doubled to $488 million TIC Solutions first-quarter revenue more than doubled to $488 million, while net loss widened to $41.5 million. Adjusted EBITDA climbed to $57.7 million. Results included NV5 Global following TIC Solutions’
05-06 18:57